{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T04:20:18Z","timestamp":1729916418282,"version":"3.28.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,25]]},"DOI":"10.7759\/cureus.72364","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T12:26:09Z","timestamp":1729859169000},"source":"Crossref","is-referenced-by-count":0,"title":["Local Cytokine Release Syndrome After Idecabtagene Vicleucel Therapy in Patients With Multiple Myeloma: Two Case Reports"],"prefix":"10.7759","author":[{"given":"Taku","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodai","family":"Kunisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Nomura-Yogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al.. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023, 388:1002-14. 10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata D","year":"2023","unstructured":"Minakata D, Ishida T, Ando K, et al.. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol. 2023, 117:729-37. 10.1007\/s12185-023-03538-6","journal-title":"Int J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03633-8","article-title":"Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma","volume":"118","author":"Nakanishi Y","year":"2023","unstructured":"Nakanishi Y, Marumo Y, Ri M, et al.. Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma. Int J Hematol. 2023, 118:647-51. 10.1007\/s12185-023-03633-8","journal-title":"Int J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0412-1","article-title":"Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed\/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy","volume":"54","author":"Jin A","year":"2019","unstructured":"Jin A, Feng J, Wang Z, Jiang L, Hu Y, Zhao K, Huang H. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed\/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2019, 54:969-72. 10.1038\/s41409-018-0412-1","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3348\/kjr.2023.1100","article-title":"CT demonstration of local cytokine-release syndrome involving the head and neck following chimeric antigen receptor T cell infusion therapy","volume":"25","author":"Ko JS","year":"2024","unstructured":"Ko JS, Lee JH, Yoon DH, Suh CH, Chung SR, Choi YJ, Baek JH. CT demonstration of local cytokine-release syndrome involving the head and neck following chimeric antigen receptor T cell infusion therapy. Korean J Radiol. 2024, 25:399-402. 10.3348\/kjr.2023.1100","journal-title":"Korean J Radiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000522669","article-title":"Cervical edema extending to the larynx as local cytokine release syndrome following chimeric antigen receptor T-cell therapy in a boy with refractory acute lymphoblastic leukemia","volume":"15","author":"Shima H","year":"2022","unstructured":"Shima H, Kurosawa T, Oikawa H, et al.. Cervical edema extending to the larynx as local cytokine release syndrome following chimeric antigen receptor T-cell therapy in a boy with refractory acute lymphoblastic leukemia. Case Rep Oncol. 2022, 15:257-62. 10.1159\/000522669","journal-title":"Case Rep Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38905","article-title":"Cervical local cytokine release syndrome following chimeric antigen receptor T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"15","author":"Inoue Y","year":"2023","unstructured":"Inoue Y, Fujino T, Chinen S, et al.. Cervical local cytokine release syndrome following chimeric antigen receptor T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Cureus. 2023, 15:e38905. 10.7759\/cureus.38905","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707191","article-title":"Case report: local cytokine release syndrome in an acute lymphoblastic leukemia patient after treatment with chimeric antigen receptor T-cell therapy: a possible model, literature review and perspective","volume":"12","author":"Luan C","year":"2021","unstructured":"Luan C, Zhou J, Wang H, et al.. Case report: local cytokine release syndrome in an acute lymphoblastic leukemia patient after treatment with chimeric antigen receptor T-cell therapy: a possible model, literature review and perspective. Front Immunol. 2021, 12:707191. 10.3389\/fimmu.2021.707191","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.24035","article-title":"Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: a case series","volume":"64","author":"Kawase S","year":"2024","unstructured":"Kawase S, Sakurai M, Masuda K, et al.. Salivary gland swelling as a characteristic manifestation of local cytokine release syndrome after anti-CD19 chimeric antigen receptor T cell therapy: a case series. J Clin Exp Hematop. 2024, 64:261-7. 10.3960\/jslrt.24035","journal-title":"J Clin Exp Hematop"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen DK","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, et al.. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023, 41:2087-97. 10.1200\/JCO.22.01365","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309776-local-cytokine-release-syndrome-after-idecabtagene-vicleucel-therapy-in-patients-with-multiple-myeloma-two-case-reports","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T12:26:10Z","timestamp":1729859170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309776-local-cytokine-release-syndrome-after-idecabtagene-vicleucel-therapy-in-patients-with-multiple-myeloma-two-case-reports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.72364","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,25]]}}}